「interpretation」の検索結果

Deep analysis of competitor patent claims: element decomposition, scope interpretation, equivalents prediction, prosecution history estoppel analysis. Automatically converts PDF/DOCX/DOC patent files to structured Markdown via patent-pdf-to-md skill before analysis. Invoke when user asks to analyze/parse competitor patent claims, decompose claim elements, assess claim scope, or perform 权利要求解析/要素分解/保护范围解读. 竞品专利权利要求深度解析：要素分解、保护范围解读、等同范围预判、审查历史限制分析。自动调用patent-pdf-to-md技能将PDF/DOCX/DOC专利文件转换为结构化Markdown后再进行分析。当用户要求解析竞品专利权利要求、要素分解、保护范围时触发。

日本語の概要は準備中です。原文の説明を表示しています。

Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.

日本語の概要は準備中です。原文の説明を表示しています。

Creates DE-specific diagnostic and result visualizations using DESeq2/edgeR built-in functions and lightweight ggplot2 wrappers. Covers MA plot (with the shrunken-LFC compression effect), volcano (with the apeglm caveat that p-values are unchanged), PCA on VST/rlog (never raw counts), sample distance heatmaps, top-DE-gene heatmaps with the row-scaling trap, dispersion / BCV plot interpretation, p-value histogram diagnostics, plotCounts for individual genes, blind=TRUE vs FALSE rationale, and the n=3 visualization stake. Use when generating DE diagnostic plots, choosing VST vs rlog for visualization, troubleshooting suspicious plot patterns (shifted MA cloud, batch-dominated PCA, anti-conservative p-value histogram), or building a standard QC figure panel.

日本語の概要は準備中です。原文の説明を表示しています。

Predict RBP binding from RNA sequence using deep learning models (RBPNet sequence-to-signal, RNAProt RNN, GraphProt2 GCN with structure, DeepCLIP, DeepRiPe multi-modal CNN) for variant-effect prediction, in silico binding-site discovery, model interpretation, and transfer learning from CLIP and RBNS datasets. Use when computational prediction of RBP binding from sequence is needed, evaluating variant effects on binding without further wet-lab experiments, comparing model performance, or training a custom model on ENCODE eCLIP data.

日本語の概要は準備中です。原文の説明を表示しています。

Classify constitutional (germline) copy number variants for clinical reporting using the 2019 ACMG/ClinGen technical standards points-based framework, with ClassifyCNV and AnnotSV for semi-automated scoring. Covers the separate copy-number-loss and copy-number-gain rubrics, the five-tier classification, ClinGen haploinsufficiency/triplosensitivity and dosage-sensitive regions, de novo and segregation evidence, and population-frequency benign evidence. Use when assigning pathogenic/likely-pathogenic/VUS/likely-benign/benign to a constitutional CNV, scoring a CNV against ACMG/ClinGen criteria, or distinguishing the automatable evidence from the case-specific evidence requiring manual input.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes base-editing screens for variant function. Covers library design (Hanna 2021 ClinVar-scale CBE screen benchmarked on BRCA1/2, Cuella-Martin 2021 DDR saturation), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end; 4-7 for ABE7.10), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.

日本語の概要は準備中です。原文の説明を表示しています。

Designs and analyzes combinatorial CRISPR screens covering paired-Cas9 (Big Papi, Najm 2018), enhanced AsCas12a multiplex (enCas12a, DeWeirdt 2021), in4mer 4-guide-array Cas12a (Esmaeili Anvar N et al 2024 Nat Commun 15:3577) and the Inzolia paralog-pair library, paralog-buffering detection (Dede 2020 Genome Biol; Thompson 2021 Nat Commun 12:1302), genetic-interaction (GI) scoring as observed_double_LFC minus expected_additive_double_LFC, synthetic-lethal and synthetic-rescue interaction interpretation, the half-of-essentiality buffered by paralogs phenomenon, multiplex screen statistical analysis with MAGeCK MLE interaction terms, and the relationship to single-cell combinatorial Perturb-seq. Use when designing a paralog or pathway-pair screen, choosing between paired-Cas9 (Big Papi) and Cas12a multiplex (Inzolia), interpreting genetic interaction scores, identifying synthetic-lethal targets for drug development, or scaling beyond single-gene CRISPR screens.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Queries gnomAD v4 (807k samples), v3, v2.1.1, and constraint metrics with grpmax FAF95, bottleneck-group exclusion, LOEUF interpretation, SV/CNV/mtDNA catalogs, and Whiffin max-credible-AF framework. Use when filtering rare variants, applying ACMG BS1/BA1, ranking genes by LoF intolerance, or selecting between v2 (GRCh37 + chrX/Y constraint) and v4 (GRCh38 + 807k samples).

日本語の概要は準備中です。原文の説明を表示しています。

Capture what someone actually said without contaminating it with your own inference. Invoke when eliciting intent in conversation (design discussion, requirement interview, decision surfacing) and when turning a conversation into a durable record (ADR, decision node, memory entry, spec `## Decisions` row). Enforces quote-before-critique, keeps illustration separate from commitment, and holds interpretation subordinate to verbatim. Prevents the failure where unspecified space is filled by the recorder and then evaluated as if the speaker had specified it.

日本語の概要は準備中です。原文の説明を表示しています。

Determines unilateral vs bilateral aldosterone excess based on cortisol-corrected aldosterone ratios from adrenal venous sampling, with ratio >4:1 indicating unilateral excess, ratio 3:1 suggestive of bilateral hypersecretion, and interpretation dependent on cosyntropin stimulation protocol used during sampling. Use when analyzing AVS results to guide surgical vs medical treatment decisions; triggers include 'AVS lateralization ratio', 'cosyntropin-stimulated AVS', 'aldosterone-to-cortisol ratio >4:1', and 'ratio 3:1 suggestive of bilateral disease'.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician asks what the 10-year ASCVD risk is, how to calculate PREVENT, PCE vs PREVENT, risk category for this patient, does my patient need a statin, 30-year risk calculation, primary prevention risk assessment. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level spectroscopy knowledge. Use when working with NMR, IR, Raman, UV-Vis, mass spectrometry, fluorescence, X-ray, electron spectroscopy, or any spectroscopic technique for structure determination or chemical analysis. Also use when the user mentions 'NMR spectroscopy', 'chemical shift', 'coupling constant', 'IR absorption', 'Raman scattering', 'UV-Vis absorption', 'fluorescence', 'XPS', 'EPR', 'mass spectrum', 'fragmentation', or 'spectral interpretation'.

日本語の概要は準備中です。原文の説明を表示しています。

Transforms data into compelling visual narratives by applying narrative structure, annotation techniques, scrollytelling patterns, and honest framing to data journalism, presentations, and infographics. Use when creating data-driven articles or reports, designing infographics with narrative, building scrollytelling experiences, annotating charts to guide interpretation, or when user mentions data storytelling, presentation design, annotated chart, narrative visualization.

日本語の概要は準備中です。原文の説明を表示しています。

How to MEASURE this repo instead of eyeballing it — interpret the loop-station context-budget trend (history.jsonl, thresholds, the tokenizer-switch gotcha), read a session trace, use the eval ledger (cost-per-success), and pick the right evidence tool (app-shots, smoke-deployed, db-counts, --check modes). Use when asked "is the harness bloating", "how big is CLAUDE.md really", "did this agent run actually succeed", "prove this works", "what evidence do we have", or when tempted to declare a capability (browser, tool) unavailable. For RUNNING the loop-station scripts, defer to the loop-station skill — this skill is interpretation + the wider evidence toolkit.

日本語の概要は準備中です。原文の説明を表示しています。

Mojibake-Reparatur für doppelt/dreifach kodiertes UTF-8. Behebt Windows-cp1252/Latin-1-Fehlinterpretationen. Ohne Abhängigkeiten.

日本語の概要は準備中です。原文の説明を表示しています。

Turns the text of a regulatory change (new regulation, amendment, rule, guidance or standard revision) into a DRAFT impact note: what changed against the prior text where supplied, who is affected as the text scopes it, an obligations table with dates and owners to confirm, and open interpretation questions for legal. States only what the text says; the rest is UNKNOWN. Use when the user asks to "brief legal on this new regulation", "list what we must do by when under this amendment", "compare the new standard with the version it replaces", "turn this directive into an obligations table" or "what does this rule mean for us". Do not use for assessing existing controls against a requirement set, use controls-gap-pack instead; for gapping a policy against a standard, use policy-gap-review. Drafts for human review; never approves, authorises or signs off.

日本語の概要は準備中です。原文の説明を表示しています。

Reviews a proposal, business case, deck or plan in character as a Chief Information Security Officer archetype and returns a DRAFT review with a verdict, findings cited to specific passages, security and compliance risks and the five interrogation questions a real CISO would ask. Use when the user asks to "run a CISO review", "pressure-test the security of this plan", "what would our CISO say about this" or "check the privacy and third-party risk". Do not use for contract, liability or regulatory-interpretation reviews, use general-counsel-reviewer instead. Drafts for human review; never approves, authorises or signs off.

日本語の概要は準備中です。原文の説明を表示しています。

Use for explicit undergraduate data-science teaching, assignment guidance, concept clarification, method selection, or output interpretation. Do not activate merely because a task contains data or Python code.

日本語の概要は準備中です。原文の説明を表示しています。

Diagnose MSBuild build performance bottlenecks using binary log analysis. Only activate in MSBuild/.NET build context. USE FOR: identifying why builds are slow by analyzing binlog performance summaries, detecting ResolveAssemblyReference (RAR) taking >5s, Roslyn analyzers consuming >30% of Csc time, single targets dominating >50% of build time, node utilization below 80%, excessive Copy tasks, NuGet restore running every build. Covers timeline analysis, Target/Task Performance Summary interpretation, and 7 common bottleneck categories. Use after build-perf-baseline has established measurements. DO NOT USE FOR: establishing initial baselines (use build-perf-baseline first), fixing incremental build issues (use incremental-build), parallelism tuning (use build-parallelism), non-MSBuild build systems. INVOKES: binlog MCP server tools (overview, errors, search, items, properties); falls back to dotnet msbuild binlog replay + grep/cat when the MCP is unavailable.

日本語の概要は準備中です。原文の説明を表示しています。

Ask clarifying questions before implementing to ensure Python requirements are understood. Use when a task lacks detail, dependencies are unclear, or multiple interpretations are possible.

日本語の概要は準備中です。原文の説明を表示しています。

Kelly Real Estate Intel: App-in-Skill daily industry intelligence cockpit for real estate and property agencies (Busabase App-in-Skill). Use when the user asks about real estate, property agencies, listings, transactions, competitor ads, client follow-up, or a地产/中介 intelligence workflow. Prepares news/source signals, buyer-intent interpretation, approved sales actions, and channel drafts for review before any external handoff.

日本語の概要は準備中です。原文の説明を表示しています。